Downgrades

Spandana Sphoorty (SPANDANA)’s 2QFY26 loss stood at ~INR2.5b (vs. MOFSLe loss of INR2.4b). NII dipped 70% YoY to ~INR1.05b (in line). Opex declined ~14% YoY to ~INR1.9b (in line).

About the stock: CreditAccess Grameen is one of the largest microfinance companies in India, having over 3 decades of experience, over 25,904 crore AUM and a strong distribution channel to provide financial aid to low-income households. It operates in over 16 states and 1 UT with 2,209 branches, having a growing employee base of 21,701 Q2FY26 performance: CreditAccess Grameen reported a sequential recovery in Q2FY26, driven by margin expansion and lower credit cost. AUM was flat QoQ (3.1% YoY) as disbursements fell 2% QoQ amid weather disruptions and slower...

We recommend a BUY on the stock with a target price of Rs 1,461/share, implying an upside of 10% from the CMP.

Ujjivan Small Finance Bank (Ujjivan) is amongst the few SFBs which had been successful in scaling loan portfolio to INR 333bn by Q1FY26 from INR 75bn in FY18 with an average credit cost of ~150bps (ex-Covid).

Gross advances grew 7.8% YoY, driven by strong momentum in small business loans (+21.9% YoY), used vehicle finance (+50.2% YoY), and housing finance (+12.0% YoY). Deposits rose 18.3% YoY, though slower CASA growth (+11.3% YoY) led to a 1.8% YoY...

We maintain our BUY recommendation on reasonable valuations.

Equitas SFB (Equitas)’s financial performance continues to be marred by elevated credit cost and a >20% QoQ decline in the high-yielding MFI portfolio.

Equitas continued to post dismal results, as it slipped into loss of Rs2.2bn, mainly due to persistent higher MFI/non-MFI stress and accelerated standard provisions on MFI loans (Rs1.9bn, mainly to ease provisioning in 9MFY26).

Equitas SFB (EQUITASB) reported a net loss of INR2.24b vs our estimate of PAT of INR220m, driven by a sharp rise in provisions due to stress in MFI and changes in the provisioning policy.

CA Grameen (Grameen) continued to improve on asset quality metrics in Q1FY26: monthly PAR 15+ accretion rate fell to 0.46% in Jun’25 vs. 0.84% in Mar’25 vs. 1.34% in Nov’24 and credit cost fell for the straight third quarter with total provisions at INR 5.7bn in Q1FY26 vs INR 5.8bn in Q4FY25 vs INR 7.5bn in Q3FY25.

declined by 10 bps compared to FY24, settling at 12.9%. Operating expenses increased by 11.0% YoY to Rs.1,108 cr. in FY25, while a decline in fee and other income led to a marginal rise in the cost-to-income ratio to 30.7%, up from 30.5% in the previous year. Despite a sharp 327.1% YoY increase in provisions due to accelerated write-offs targeting delinquent accounts, the company reported an annual profit of Rs.531.4 cr. Gross NPA and Net NPA rose sharply to 4.8% and 1.7%, respectively, from 1.2% and 0.4% in FY24, reflecting a notable deterioration across all PAR buckets. While collection efficiency remained subdued for the first three quarters of the year, it showed signs of recovery towards the end of FY25, indicating early momentum in asset quality stabilization....

We recommend a BUY rating on the stock with a target price of Rs 74/share, implying an upside of 11% from the CMP.

Spandana Sphoorty’s (SPANDANA) 4QFY25 loss stood at ~INR4.3b (vs. MOFSLe loss of INR4.1b). FY25 loss stood at INR10.3b (vs. PAT of INR5b in FY24).

expected to support earnings recovery. The bank is projected to exit FY26 with a Return on Assets (ROA) of 1% and sustain an ROA above 1% throughout FY27. With stress in the microfinance segment subsiding, we assign an "Accumulate" rating to the stock, with a target price of 68, based on 1.1x FY27E Book Value per Share (BVPS)....

We maintain our BUY recommendation on the stock

Equitas SFB (EQUITASB) reported 4QFY25 PAT of ~INR421m, down 37% QoQ and 43% below our est., due to lower other income and higher-thanexpected provisions.

AU SFB continues to grow its credit portfolio at a healthy pace, defying industry trend and the declining MFI/Card book. However, higher CoF and interest reversal on MFI/Card NPAs has led to continued margin correction (10bps QoQ).

Black & White report

We recommend a BUY rating on the stock with a target price of Rs 622/share, implying an upside of 10% from the CMP.

Fusion Finance (Fusion) has bolstered its balance sheet by upping its provision cover across Stage-1/2/3 assets and de-recognising interest income on Stage-3 assets.